PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

🕻 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. RUPINDER KAUR			
AGE/ GENDER	: 31 YRS/FEMALE	PATIENT	ID	: 1595972
COLLECTED BY	:	REG. NO./	LAB NO.	: 122408300001
REFERRED BY	:	REGISTR	ATION DATE	: 30/Aug/2024 08:53 AM
BARCODE NO.	: 12504373	COLLECT	ION DATE	: 30/Aug/2024 09:21AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITU	TE REPORTI	NG DATE	: 30/Aug/2024 01:01PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBAL	A CITY - HARYANA		
Test Name		Value	Unit	Biological Reference interval
		HAEMATOLOG	βY	
		HAEMOGLOBIN (
HAEMOGLOBIN (HB)	13.1	gm/dL	12.0 - 16.0
by CALORIMETRIC			ů,	
<u>INTERPRETATION:-</u> Hemoglobin is the pr	otein molecule in red blood cells that	carries oxygen from th	e lungs to the b	odys tissues and returns carbon dioxide from t
tissues back to the lu	ings.	50	e langs to the b	
A low hemoglobin lev ANEMIA (DECRESED	vel is referred to as ANEMIA or low red	I blood count.		
1) Loss of blood (trau	umatic injury, surgery, bleeding, colon	cancer or stomach ulc	er)	
2) Nutritional deficie	ncy (iron, vitamin B12, folate)			
 Bone marrow prob Suppression by rot 	plems (replacement of bone marrow by d blood cell synthesis by chemotherap	y cancer)		
5) Kidney failure	a blood cell synthesis by chemotherap	by unugs		
6) Abnormal hemogle	obin structure (sickle cell anemia or tl	halassemia).		
	REASED HAEMOGLOBIN): Ititudes (Physiological)			
2) Smoking (Seconda	ry Polycythemia)			
3) Dehydration produ	uces a falsely rise in hemoglobin due t	o increased haemocon	centration	
	ease (for example, emphysema)			
5) Certain tumors	oone marrow known as polycythemia r	ubra vora		
7) Abuse of the drug	erythronoetin (Enogen) by athletes for	r blood doning purpose	s (increasing the	e amount of oxygen available to the body by

7) Abuse of the drug erythropoetin (Epogen) by athletes for blood doping purposes (increasing the amount of oxygen available to the body by chemically raising the production of red blood cells).

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600, REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. RUPINDER KAUR				
AGE/ GENDER	: 31 YRS/FEMALE		ENT ID	: 1595972	
COLLECTED BY	:	REG.	NO./LAB NO.	: 122408300001	
REFERRED BY	:	REGI	STRATION DATE	: 30/Aug/2024 08:53 AM : 30/Aug/2024 09:21AM	
BARCODE NO.	: 12504373	COLI	ECTION DATE		
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE		DRTING DATE	: 30/Aug/2024 01:01PM	
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD	, AMBALA CITY - HARYAN			
Test Name		Value	Unit	Biological Reference interval	
	CL	INICAL CHEMISTRY	/BIOCHEMISTR	Y	
		LIPID PROFILE	: BASIC		
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP		156.95	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.1	
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		90.78	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0	
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		58.79	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		80	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0	
NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		98.16	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0	
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY		18.16	mg/dL	0.00 - 45.00	
		404.68	mg/dL	350.00 - 700.00	
CHOLESTEROL/HDL by CALCULATED, SPE	RATIO: SERUM	2.67	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0	
	NUM	1.36	RATIO	LOW RISK: 0.50 - 3.0	

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)**



P K R JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

RATIO

A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. RUPINDER KAUR				
AGE/ GENDER	: 31 YRS/FEMALE	PATIENT ID	: 1595972		
COLLECTED BY	:	REG. NO./LAB NO.	: 122408300001		
REFERRED BY	:	REGISTRATION DATE	: 30/Aug/2024 08:53 AM		
BARCODE NO.	: 12504373	COLLECTION DATE	: 30/Aug/2024 09:21AM		
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 30/Aug/2024 01:01PM		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA				
Test Name	Value	Unit	Biological Reference interval		

by CALCULATED, SPECTROPHOTOMETRY

TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY **INTERPRETATION:**

1. Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 wears with a threat the line total should be screened for lipid status.

1.54^L

age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

* End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)**



MODERATE RISK: 3.10 - 6.0

HIGH RISK: > 6.0

3.00 - 5.00